Patients with acute coronary syndromes should received statins

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

JAMA cardiology·2026

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.

The lancet. Diabetes & endocrinology·2025

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

JAMA cardiology·2024

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.

European heart journal·2022

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.

Journal of clinical lipidology·2022

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.

Journal of cardiovascular pharmacology·2021

Exercise After Coronary Stenting: Potential Effects on in-Stent Restenosis.

Current atherosclerosis reports·2026

Novel Lipoprotein (a) Therapies: A Comprehensive Review.

Current atherosclerosis reports·2026

Exercise and Cardiovascular Risk Modulation in Post-COVID Syndrome.

Current atherosclerosis reports·2026

Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists.

Current atherosclerosis reports·2026

Dietary Interventions for Hypertriglyceridemia.

Current atherosclerosis reports·2026

Exercise Training and Heart Rate Variability: A Guided Optimization of Cardiorespiratory Fitness in Cardiometabolic Disease.

Current atherosclerosis reports·2026

Fractional exhaled nitric oxide is a non-invasive disease activity marker of IgG4-related disease.

Rheumatology (Oxford, England)·2026

Coronary CT angiography-derived perivascular fat attenuation index as a potential marker for heart failure in hypertrophic cardiomyopathy.

The British journal of radiology·2026

Myocardial Calcification After Severe Sepsis: 3-Patient Case Series, Multimodality Imaging, and Review of the Literature.

JACC. Case reports·2026

One-Step Immobilized Phage Depolymerase Coatings for Catheter-Related Bloodstream Infections.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Inhibition of Dyrk1a attenuates type 1 diabetic cardiomyopathy via anti‑ferroptosis.

Molecular medicine reports·2026

BIOCARD framework: integrating fecal bile acids, lipids, and metabolites to assess response to a cardiovascular health intervention.

Gut microbes·2026

Related Experiment Videos

Patients with acute coronary syndromes should received statins

Related Concept Videos

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.

Exercise After Coronary Stenting: Potential Effects on in-Stent Restenosis.

Novel Lipoprotein (a) Therapies: A Comprehensive Review.

Exercise and Cardiovascular Risk Modulation in Post-COVID Syndrome.

Finerenone in Heart Failure with Preserved Ejection Fraction: Expanding the Role of Non-steroidal Mineralocorticoid Receptor Antagonists.

Dietary Interventions for Hypertriglyceridemia.

Exercise Training and Heart Rate Variability: A Guided Optimization of Cardiorespiratory Fitness in Cardiometabolic Disease.

Fractional exhaled nitric oxide is a non-invasive disease activity marker of IgG4-related disease.

Coronary CT angiography-derived perivascular fat attenuation index as a potential marker for heart failure in hypertrophic cardiomyopathy.

Myocardial Calcification After Severe Sepsis: 3-Patient Case Series, Multimodality Imaging, and Review of the Literature.

One-Step Immobilized Phage Depolymerase Coatings for Catheter-Related Bloodstream Infections.

Inhibition of Dyrk1a attenuates type 1 diabetic cardiomyopathy via anti‑ferroptosis.

BIOCARD framework: integrating fecal bile acids, lipids, and metabolites to assess response to a cardiovascular health intervention.

Related Experiment Videos

Patients with acute coronary syndromes should received statins

Related Concept Videos

Related Articles